EHA 2022 | Treatment options for myeloma patients who relapse after BCMA-directed therapies
Juan Du
• 13 Jun 2022
Juan Du, MD, Changzheng Hospital, The Second Military Medical University, Shanghai, China, discusses treatment options for myeloma patients who relapse or are refractory to BCMA-directed therapies. Dr Du explains that while carfilzomib-based regimens and anti-CD38 antibodies are promising, more head-to-head comparison trials are required to improve options for patients. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.
